Effectiveness of primary care interventions for weight management in children and adolescents an updated, targeted systematic review for the USPSTF
Only one medication (orlistat) is FDA-approved for use in children and adolescents, and it is approved for prescription use in those 12 years and older. CONCLUSIONS: The research evaluating the treatment of obese children and adolescents has improved in terms of quality and quantity in the past seve...
| Main Author: | |
|---|---|
| Corporate Authors: | , , |
| Format: | eBook |
| Language: | English |
| Published: |
Rockville, MD
Agency for Healthcare Research and Quality
2010, [2010]
|
| Series: | Evidence syntheses
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Only one medication (orlistat) is FDA-approved for use in children and adolescents, and it is approved for prescription use in those 12 years and older. CONCLUSIONS: The research evaluating the treatment of obese children and adolescents has improved in terms of quality and quantity in the past several years. While there are still significant gaps in our understanding of obesity and overweight treatment in children and adolescents, current research suggests that behavioral interventions can be effective in managing weight in obese children and adolescents. Combined behavioral-pharmacological interventions may be useful in very obese adolescents, particularly if research confirms that weight loss is maintained Comprehensive behavioral interventions involving medium- to high-intensity interventions were the most effective behavioral approach and consistently resulted in small to moderate short-term improvements, with a weighted mean difference in BMI change of 2.4 kg/m2 between groups. More limited evidence suggests that these improvements can be maintained completely (or somewhat) over the 12 months following the end of treatments, and that there are few harms with behavioral interventions. Two medications (sibutramine, orlistat) combined with behavioral interventions resulted in small to moderate short-term weight loss in very obese adolescents (BMI reduction of 2.6 kg/m2 more than behavioral treatment plus placebo for sibutramine, 0.85 kg/m2 for orlistat); however, no studies followed weight changes after medication use ended. Potential side effects were greater than for behavioral interventions and varied in severity. We searched Ovid MEDLINE(r), PsycINFO, Database of Abstracts of Reviews of Effects, the Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, and Education Resources Information Center from 2005 (2003 for pharmacological studies) to June 10, 2008 to identify literature that was published after the search dates of prior relevant systematic reviews; we also examined reference lists of five other good-quality systematic reviews and of included trials, and considered experts' recommendations. From the two good quality systematic reviews and 2786 abstracts, we identified 25 trials in 30 publications that addressed our research questions. OBJECTIVES: To examine behavioral and pharmacological weight management interventions for overweight (defined as BMI greater or equal to 85th to 94th percentile of age- and sex-specific norms) and/or obese (BMI greater or equal to 95th percentile) children and adolescents which are feasible to conduct in primary care settings or that may be available for referral from primary care in order to update an identified gap in the previous report on childhood obesity for the United States Preventive Services Task Force (USPSTF). DATA SOURCES: We identified two good quality systematic reviews published after the previous USPSTF review that addressed our research questions. REVIEW METHODS: After review by two investigators against pre-determined inclusion/exclusion criteria, we included fair-to-good quality trials to evaluate the effects of treatment on weight and weight-related co-morbidities; we would have included large comparative cohort studies to evaluate longer term followup and harms of treatment if they had been available. Investigators abstracted data into standard evidence tables with abstraction checked by a second investigator. Studies were quality-rated by two investigators using established criteria. RESULTS: Available research primarily enrolled obese (rather than overweight) children and adolescents aged 4 to 18 years and no studies targeted those less than 4 years of age. |
|---|---|
| Item Description: | Title from PDF t.p. - "Contract Number: 290-2007-10057-I; Task order number 3.". - "January 2010.". - Mode of access: Internet |
| Physical Description: | 1 PDF file (v, 66 p.) |